Prime Medicine

Biotech · Public

Prime editing platform for precise in vivo gene correction

primemedicine.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
0 granted · 40 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1421NEUMEDICINES, INC.——
1422Rectify Pharmaceuticals LLC——
1423MOLECULAR THERANOSTICS, LLC——
1424Prime Medicine——
1425Guide Star Biosciences, Inc.—$925K
1426Gamma Therapeutics, Inc.——
1427Solutions BioMed LLC—$5.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 40
  • Genome Editing Compositions and Methods for Treatment of Friedreich's Ataxiaapplication
  • Split Prime Editorsapplication
  • Genome Editing Compositions And Methods For Treatment Of Fuchs Endothelial Corneal Dystrophyapplication
  • Modified Prime Editing Guide Rnasapplication
  • Methods And Compositions For Inhibiting Mismatch Repairapplication
  • Genome Editing Compositions And Methods For Treatment Of Chronic Granulomatous Diseaseapplication
  • Genome Editing Compositions And Methods For Treatment Of Glycogen Storage Disease Type 1Bapplication
  • Genome Editing Compositions And Methods For Treatment Of Fragile X Syndromeapplication
  • Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosisapplication
  • Genome Editing Compositions And Method For Treatment Of Retinitis Pigmentosaapplication
  • Genome Editing Compositions And Methods For Treatment Of Usher Syndrome Type 3application
  • Genome Editing Compositions And Methods For Treatment Of Fanconi Anemiaapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.